期刊
CLINICAL CANCER RESEARCH
卷 27, 期 17, 页码 4667-4668出版社
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1078-0432.CCR-21-1778
关键词
-
类别
A phase I study found a tolerable combination of the ATR inhibitor ceralasertib with paclitaxel showed responses in melanoma patients who had progressed on an immune check-point inhibitor. Further exploration is needed to determine the extent and molecular determinants of clinical activity.
A phase I study defined a tolerable combination of the ATR inhibitor ceralasertib with paclitaxel and responses were seen in patients with melanoma who had progressed on an immune check-point inhibitor. This combination warrants further exploration to determine the extent and molecular determinants of clinical activity.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据